EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy

Renwang Liu, Yiming Meng, Mohamed Rahouma

Frontiers in Pharmacology · 26.03.2026 · 17

DOI: 10.3389/fphar.2026.1744580 ↗

Kurz gefasst

Editorial in der Zeitschrift Frontiers in Pharmacology, online erschienen am 26.03.2026. Verfasst von Renwang Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lung Cancer Surgery, Center of Thoracic Surgery, Tianjin Medical University General Hospital, Tianjin, China. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death, and immune 21 checkpoint inhibitors (ICIs) have revolutionized its treatment by reactivating the immune system to tumor cells [1,2] . Despite significant improvements in patient outcomes, ICIs present 23 several key challenges: inconsistent efficacy across populations, complex resistance mechanisms, 24 and treatment-related toxicities [2,3]

Schlagwörter

Stichwörter der Autor:innen

NSCLCbiomarkerscombination therapydrug resistanceimmune checkpoint inhibitor

Autor:innen und Institutionen

  • Department of Lung Cancer Surgery, Center of Thoracic Surgery, Tianjin Medical University General Hospital, Tianjin, China.
  • Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China.
  • Department of Central Laboratory, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China.
  • Cardiothoracic Surgery Department, Weill Cornell Medicine, New York, NY, United States.
  • Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, R., Meng, Y., & Rahouma, M. (2026). Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1744580

Vancouver

Liu R, Meng Y, Rahouma M. Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1744580

BibTeX
@article{Liu2026,
  author = {Liu, Renwang and Meng, Yiming and Rahouma, Mohamed},
  title = {Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1744580}
}
Kostenlos starten →